Searched for
ITOLIZUMAB
Health ministry decides against including Itolizumab in clinical management protocols for COVID-19The permission to market the drug was granted for the treatment of cytokine release syndrome in 'moderate' to 'severe' Acute Respiratory Di...26 Jul, 2020, 09.23 PM IST- Biocon Q1 results: Net profit declines 28% to Rs 149 croreThe Bengaluru-headquartered biopharma company’s revenue was up 14% at Rs 1,690 crore during the quarter.24 Jul, 2020, 02.13 PM IST
- Top-level task force finds anti-parasitic drug ivermectin ineffective against coronavirusIn a meeting held on July 14 to review the evidence, the task force headed by Niti Aayog member VK Paul decided against recommending the dr...17 Jul, 2020, 10.18 AM IST
- Biocon defends limited trial patients for Itolizumab nod, says followed science of "highest order"The company is marketing the drug as a replacement to Roche Pharma’s Tocilizumab (originally approved for rheumatoid arthritis) that is cur...14 Jul, 2020, 12.05 PM IST
- Biocon jumps 10%, hits 52-week high as DCGI approves use of Itolizumab on Covid-19 patientsThe drug, which is also used to cure the skin disease psoriasis, was cleared by the Drug Controller General of India (DCGI) for usage in In...13 Jul, 2020, 08.15 PM IST
- Biocon to launch drug for COVID-19 patients; priced at Rs 8,000 per vialNew Delhi, Jul 13 () Biotechnology major Biocon on Monday said it will launch biologic drug Itolizumab for the treatment of moderate to sev...13 Jul, 2020, 08.14 PM IST
- Biocon’s biosimilar for treating Covid-19: Patients responded positively, says Kiran Mazumdar-ShawThe Drug Controller General of India (DGCI) has permitted the Bengaluru-headquartered drug maker to market Itolizumab (ALZUMab) injection 2...12 Jul, 2020, 02.55 PM IST
- Biocon gets DCGI nod to use Itolizumab in moderate to severe Covid-19 patientsBiocon said the approval is based on the results from the successful conclusion of a randomized, controlled clinical trial at multiple hosp...11 Jul, 2020, 05.12 PM IST
- Drug regulator okays psoriasis injection for limited use in treating COVID-19 patientsConsidering the unmet medical needs to treat COVID-19, Drugs Controller General of India Dr V G Somani approved monoclonal antibody injecti...11 Jul, 2020, 01.07 PM IST
- Biocon says use of Itolizumab in COVID-19 treatment encouragingBiocon has witnessed encouraging results in the use of its novel biologic Itolizumab for treating some Covid-19 related conditions, the pha...16 May, 2020, 09.11 AM IST
- Old drug brings new hope for critically ill coronavirus patientsBMC-run hospitals have successfully tried an immunomodulatory drug to treat extremely critical cases.03 May, 2020, 03.26 PM IST
- Biocon extends licensing pact with Equillium for itolizumabItolizumab, a first-in-class humanized anti-CD6 monoclonal antibody, is developed by Biocon and launched in 2013 in India under the brand n...12 Dec, 2019, 08.13 PM IST
- Biocon seeking partners to develop, market psoriasis drugBiotechnology major Biocon today said it is looking for partners to develop and market its novel biologic drug Itolizumab05 Jun, 2013, 04.58 PM IST
- Biocon to launch psoriasis drug novel biologic in JulyThe company had received marketing authorisation for Itolizumab from the Drugs Controller General of India (DCGI) in January, 2013.28 Apr, 2013, 11.39 AM IST
- Biocon gets DCGI approval to market anti-psoriasis drug, Itolizumab"The company has received market authorisation from the DCGI for its novel biologic Itolizumab, for treatment of chronic plaque psoriasis,"...08 Jan, 2013, 02.27 PM IST
- Biocon to focus on regional allies for commercialisationBiocon is altering its product commercialisation strategy by eyeing to partner with many regional players rather than joining hands with a ...29 Jul, 2012, 01.48 PM IST
- HSBC recommends ‘overweight’ rating on BioconHSBC has recommended ‘Overweight’ rating on Biocon with a target price of Rs 270.27 Jul, 2012, 08.22 PM IST
Load More
